Pediatric Research

Nathan Kuppermann, M.D., M.P.H., named chief academic officer and chair of Pediatrics at Children’s National Hospital

Retrieved on: 
Wednesday, March 13, 2024
JAMA, Research, Health care, Health, Public, Public health, EVP, UCSF School of Medicine, Pediatric Research, Education, UC, Global Health, Emergency medicine, Society, Publication, Emergency medical services, Hospital, Children's National Hospital, Stanford University, National academy, MHA, Pediatrics, BMJ

Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.

Key Points: 
  • Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.
  • He comes to Children’s National from UC Davis Health and UC Davis School of Medicine in Sacramento, CA, and will start in September.
  • After a national search, Dr. Kuppermann stood out for his exceptional contributions to clinical and academic research, focusing on pediatric emergency care, and his dedication to mentorship.
  • He completed a pediatrics residency and chief residency at Harbor-UCLA Medical Center and a fellowship in Pediatric Emergency Medicine at Boston Children's Hospital.

Natalia Gomez-Ospina, MD, PhD is the Recipient of the 2024 Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award from the ACMG Foundation for Genetic and Genomic Medicine

Retrieved on: 
Wednesday, March 13, 2024
Research, Partner, Brain, B cell, FACMG, Gaucher's disease, Assistant, Pediatric Research, American Journal, Patient, Medical genetics, DSM-IV codes, Glycogen storage disease, System, Young Scientist Award, Gene therapy, Doctor of Philosophy, Stanford University, Protein, Genome, American College, Mucopolysaccharidosis, Genomics, Society, Hospital, Genetic, Cell, Young, Genetic distance, Hurler syndrome, Lucile Packard Children's Hospital

BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Natalia Gomez-Ospina, MD, PhD is the recipient of the ACMG Foundation for Genetic and Genomic Medicine's 2024 Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award—the "Watson Award"—named for the American College of Medical Genetics and Genomics first and longstanding executive director, Michael S. Watson, MS, PhD, FACMG.

Key Points: 
  • BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Natalia Gomez-Ospina, MD, PhD is the recipient of the ACMG Foundation for Genetic and Genomic Medicine's 2024 Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award—the "Watson Award"—named for the American College of Medical Genetics and Genomics first and longstanding executive director, Michael S. Watson, MS, PhD, FACMG.
  • "I am honored to receive this award in recognition of my dedication to advancing genetic and genomic medicine and my commitment to making a positive difference in the lives of patients with genetic diseases.
  • This award affirms the need for innovative approaches to treat such diseases and the immense potential that genome editing has in this regard.
  • "Dr. Gomez-Espina is a promising physician-scientist whose work is befitting the Dr. Michael Watson Genetic and Genomic Medicine Innovation Award, an award that honors an individual whose work has had a significant impact on genetic and genomic medicine.

Two Research Leaders from CHOP Elected to National Academy of Medicine

Retrieved on: 
Monday, October 9, 2023
Edmond, Health, National Academy of Medicine, Doctor of Philosophy, Epidemiology, Death, LCHS, Research, Public, National academy, Nephrology, Pediatrics, PI, NAM, Patient-Reported Outcomes Measurement Information System, Pediatric Research, Institute of Medicine, Nepal, Perelman School of Medicine at the University of Pennsylvania, University, Kidney, CHOP, Medicine, Hospital, Philadelphia, Society, Society for Pediatric Research, Chronic kidney disease, PROMIS, Policy, Science, Natural history, Child, Children's Hospital of Philadelphia, NIH, Management, Nursing, MD

PHILADELPHIA, Oct. 9, 2023 /PRNewswire/ -- Two renowned experts from Children's Hospital of Philadelphia (CHOP) have been elected to the National Academy of Medicine (NAM), effective October 1, 2023. CHOP Chief Scientific Officer Susan Furth, MD, PhD, and CHOP pediatrician and PEDSnet founder Christopher B. Forrest, MD, PhD, have both been recognized for outstanding professional achievement. An election to NAM is considered one of the highest honors in health and medicine.

Key Points: 
  • CHOP Chief Scientific Officer Susan Furth , MD, PhD, and CHOP pediatrician and PEDSnet founder Christopher B. Forrest , MD, PhD, have both been recognized for outstanding professional achievement.
  • In addition to her nephrology research, Dr. Furth is Chief Scientific Officer and Executive Vice President at CHOP, where she oversees the CHOP Research Institute and its more than 1,000 investigators and 2,600 employees.
  • He is the Director and Founder of PEDSnet , a national pediatric learning health system, which is one of the PCORnet Clinical Research Networks.
  • Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, the NAM addresses critical issues in health, science, medicine, and related policy.

RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS

Retrieved on: 
Monday, August 28, 2023
Morgan Stanley, Maimonides Medical Center, IPO, IOMA, ALZA, Pediatrics, Biochemistry, Physician, Columbia University Vagelos College of Physicians and Surgeons, OTCQB, Brandeis University, Pediatric Research, Research, RNA, Associate, Professor, Columbia, Supergene, Surgeon, Steroid, Pharmaceutical industry, Medical device, SUNY

PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™.

Key Points: 
  • PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™.
  • As RetinalGeniX DNA-GPS™ seeks to evolve into a diagnostic and therapeutic company, it plans to use pharmacogenetic mapping and high-resolution imaging RetinalGeniX DNA-GPS to validate and guide the development of novel methods and therapeutic products.
  • “Dr.
  • We welcome the expertise that Fred brings to RetinalGeniX DNA-GPS to assist in the development of this new technology in healthcare,” said Dr. Larry Perich, Director of the DNA/GPS program at RetinalGeniX.

Oberkotter Foundation Adds to Leadership

Retrieved on: 
Tuesday, August 22, 2023
Addition, Incoming, Senior, Marketing, Teaching, Communication, Pediatric Research, Research, CCC, SR, Audiology, Hearing, Robert, M.A, Management, Medical device, Innovation, Sonova

PHILADELPHIA, Aug. 22, 2023 /PRNewswire/ -- The Oberkotter Foundation, a philanthropic leader advancing opportunities for children who are deaf or hard of hearing to learn to listen and talk, welcomes Andrea Hillock Dunn, Au.D., Ph.D., CCC-A as Vice President, Programs and Amy Schamp, M.A., as Senior Director, Communications. 

Key Points: 
  • She will work with Dr. Teresa Caraway, Incoming CEO, and Dr. Jace Wolfe, Senior Vice President, Innovation, to further the initiatives of the Foundation.
  • She comes to the foundation from Phonak, Sonova Group as the former Global Director of Pediatric Research.
  • Ms. Schamp comes to the role with expertise from many years with the Robert Wood Johnson Foundation where she led the digital strategy for both brand and marketing.
  • "Dr. Dunn and Ms. Schamp are highly regarded experts in their fields and are excellent additions to our team to further new strategic initiatives of the Oberkotter Foundation in the coming years," states Dr. Teresa Caraway, Incoming Chief Executive Officer of Oberkotter Foundation.

Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Retrieved on: 
Tuesday, December 6, 2022
GMP, Degenerative disease, Research, ASX, Autoimmune disease, Cytokine, Cancer, Pediatric Research, IL-6, Disease, IND, CDMO, IMM, Vaccine

SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been established for IMP761, its proprietary preclinical candidate for autoimmune diseases. The 200L scale attained by Northway Biotech, an end-to-end biopharmaceutical contract development and manufacturing organisation (CDMO), will ensure supply of IMP761 for IND-enabling studies and ensuing clinical trials.

Key Points: 
  • An engineering and a GMP manufacturing run at 200L have been successfully performed for bulk drug substance and final filled drug product, proving the robustness and reproducibility of the developed manufacturing process.
  • Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease.
  • The Company is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
  • Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep’s large pharmaceutical partners.

Zika-exposed children may display neurodevelopmental differences

Retrieved on: 
Wednesday, November 30, 2022
Children's National Hospital, U.S. News & World Report, CZS, Human, Harwell Science and Innovation Campus, Zika virus, Hospital, Parent, Mother, Knowledge, Health, Pediatric Research, Research, Potyvirus, Parenting, Child, Virus, Memory, Ageing, News, Severe acute respiratory syndrome coronavirus 2, Pregnancy, Vertically transmitted infection, Nursing, Vaccine, Toy, Zika fever, D.C

These findings are another piece of the puzzle that provides insight into the long-term neurodevelopment of children with prenatal Zika virus exposure.

Key Points: 
  • These findings are another piece of the puzzle that provides insight into the long-term neurodevelopment of children with prenatal Zika virus exposure.
  • Parents of Zika-exposed children reported significantly lower levels of mobility and responsibility compared to control children, although differences in cognitive function scores were not significant.
  • Additionally, parents of 6 (11%) Zika-exposed children reported mood problems compared to 1 (1%) of control children, and Zika-exposed parents were significantly more likely to report parental distress.
  • Some differences in results may also have been caused by the age and therefore developmental differences between the groups of children.

New Clinical Trial Finds Seed's Pediatric Synbiotic PDS-08™ Impacts Gut Microbiome and Bowel Movements in Children

Retrieved on: 
Wednesday, November 2, 2022
Population, European Society of Neurogastroenterology and Motility, Health, Weill Cornell Medicine, Pain, Science, European Society for Paediatric Research, Pediatric Research, Abdominal pain, Physiology, Bacteria, Reproductive health, Biophysical environment, Mental health, Society for Pediatric Research, Biophysics, Research, Defecation, Pediatrics, Hospital, Maintenance, Seed, Education, American Pediatric Society, Laxative, Skin, Communication, GI, Biodiversity, Cramp, Solution, Ecology, Probiotic, Quality of life, Society, Nutritional science, Caregiver, Constipation, Parent, Dietary supplement, Texas Children's Hospital, Bifidobacterium

LOS ANGELES, Nov. 2, 2022 /PRNewswire/ -- Seed Health, a microbiome science company pioneering innovations in probiotics, today announced the publication of a double-blind, placebo-controlled clinical study in Pediatric Research (Nature Portfolio) –– the official journal of the American Pediatric Society, the European Society for Paediatric Research, and the Society for Pediatric Research. The study demonstrates the clinical potential of Seed Health's first pediatric synbiotic offering, PDS-08™ Pediatric Daily Synbiotic, in children with intermittent constipation. Christopher E. Mason, Ph.D., Professor of Physiology and Biophysics at Weill Cornell Medicine, led the bioinformatics analysis, including the generation of novel insights into the role of the gut microbiome in pediatric gastrointestinal (GI) health.

Key Points: 
  • The study demonstrates the clinical potential of Seed Health's first pediatric synbiotic offering, PDS-08 Pediatric Daily Synbiotic , in children with intermittent constipation.
  • Children with intermittent constipation (less than five weekly bowel movements, or WBMs) experienced an increase in regular, healthy WBMs while taking PDS-08 .
  • "These findings represent the next frontier in probiotics and deepen our understanding of the pediatric gut microbiome."
  • LUCA Biologics , Seed Health's biotechnology company co-founded with Dr. Jacques Ravel, develops living medicines targeting the vaginal microbiome for urogenital and reproductive health.

New Clinical Trial Finds Seed's Pediatric Synbiotic PDS-08™ Impacts Gut Microbiome and Bowel Movements in Children

Retrieved on: 
Wednesday, November 2, 2022
Population, European Society of Neurogastroenterology and Motility, Health, Weill Cornell Medicine, Pain, Science, European Society for Paediatric Research, Pediatric Research, Abdominal pain, Physiology, Bacteria, Reproductive health, Biophysical environment, Mental health, Society for Pediatric Research, Biophysics, Research, Defecation, Pediatrics, Hospital, Maintenance, Seed, Education, American Pediatric Society, Laxative, Skin, Communication, GI, Biodiversity, Cramp, Solution, Ecology, Probiotic, Quality of life, Society, Nutritional science, Caregiver, Constipation, Parent, Dietary supplement, Texas Children's Hospital, Bifidobacterium

LOS ANGELES, Nov. 2, 2022 /PRNewswire/ -- Seed Health, a microbiome science company pioneering innovations in probiotics, today announced the publication of a double-blind, placebo-controlled clinical study in Pediatric Research (Nature Portfolio) –– the official journal of the American Pediatric Society, the European Society for Paediatric Research, and the Society for Pediatric Research. The study demonstrates the clinical potential of Seed Health's first pediatric synbiotic offering, PDS-08™ Pediatric Daily Synbiotic, in children with intermittent constipation. Christopher E. Mason, Ph.D., Professor of Physiology and Biophysics at Weill Cornell Medicine, led the bioinformatics analysis, including the generation of novel insights into the role of the gut microbiome in pediatric gastrointestinal (GI) health.

Key Points: 
  • The study demonstrates the clinical potential of Seed Health's first pediatric synbiotic offering, PDS-08 Pediatric Daily Synbiotic , in children with intermittent constipation.
  • Children with intermittent constipation (less than five weekly bowel movements, or WBMs) experienced an increase in regular, healthy WBMs while taking PDS-08 .
  • "These findings represent the next frontier in probiotics and deepen our understanding of the pediatric gut microbiome."
  • LUCA Biologics , Seed Health's biotechnology company co-founded with Dr. Jacques Ravel, develops living medicines targeting the vaginal microbiome for urogenital and reproductive health.

JPMA Cares to Honor Dr. Sadiqa Kendi with the 2022 Impact Award

Retrieved on: 
Tuesday, November 1, 2022
Johns Hopkins Bloomberg School of Public Health, American Academy, Yale school, Child, Health, Children, Boston University School of Medicine, Emergency medicine, Pediatric Research, Division, Juvenile Products Manufacturers Association, Industry, Yale School of Medicine, Children's Hospital at Montefiore, Society for Pediatric Research, Research, Pediatrics, Human, Safety, Hospital, Digital Impact Awards Africa, Education, Public health, Food, Family Promise, Associate, Philadelphia, Social change, Music, Health equity, Boston Medical Center, United Nations Foundation, Montefiore, Society, Children's Hospital of Philadelphia, JPMA, Parent, Medicine, Toy, Online shopping, Injury, Crayon, Violence

MOUNT LAUREL, N.J., Nov. 1, 2022 /PRNewswire-PRWeb/ -- JPMA Cares is pleased to announce Dr. Sadiqa Kendi as the organization's 2022 Impact Award winner. Dr. Kendi serves as the Division Chief of the Pediatric Emergency Medicine Division and Associate Professor of Pediatrics at Boston Medical Center and Boston University School of Medicine. She is an expert in pediatric injury prevention, with a focus on health equity.

Key Points: 
  • JPMA Cares is pleased to announce Dr. Sadiqa Kendi as the organization's 2022 Impact Award winner.
  • MOUNT LAUREL, N.J., Nov. 1, 2022 /PRNewswire-PRWeb/ -- JPMA Cares is pleased to announce Dr. Sadiqa Kendi as the organization's 2022 Impact Award winner.
  • "We are thrilled to recognize Dr. Sadiqa Kendi for the tremendous work she's doing to make a positive impact on the long-term success of babies and young children," said Executive Director of JPMA and JPMA Cares Lisa Trofe.
  • "I'm honored to be recognized with the JPMA Cares Impact Award," said Dr. Kendi.